Filtered By:
Condition: Diabetes Mellitus
Nutrition: Weight Loss

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 91 results found since Jan 2013.

Pharmacotherapy of obesity: clinical treatments and considerations.
Abstract Obesity is a world-wide epidemic associated with significant morbidity and mortality which costs billions of dollars per year. The associated related conditions are many and include heart disease, stroke, type II diabetes mellitus, sleep apnea and certain types of cancer. Given that it is a multifactorial problem, the treatments must also address the numerous causes associated with the development of obesity. The neurohormonal regulation of feeding and energy is a complex system often necessitating modification through more than 1 pathway to achieve weight loss. Therefore, in addition to lifestyle changes...
Source: The American Journal of the Medical Sciences - April 1, 2013 Category: Journals (General) Authors: Holes-Lewis KA, Malcolm R, O'Neil PM Tags: Am J Med Sci Source Type: research

Should visceral fat be reduced to increase longevity?
Abstract Several epidemiologic studies have implicated visceral fat as a major risk factor for insulin resistance, type 2 diabetes mellitus, cardiovascular disease, stroke, metabolic syndrome and death. Utilizing novel models of visceral obesity, numerous studies have demonstrated that the relationship between visceral fat and longevity is causal while the accrual of subcutaneous fat does not appear to play an important role in the etiology of disease risk. Specific recommended intake levels vary based on a number of factors, including current weight, activity levels, and weight loss goals. It is discussed the nee...
Source: Ageing Research Reviews - June 10, 2013 Category: Genetics & Stem Cells Authors: Finelli C, Sommella L, Gioia S, La Sala N, Tarantino G Tags: Ageing Res Rev Source Type: research

Selenium Treatment and Chagasic Cardiopathy (STCC): study protocol for a double-blind randomized controlled trial
DiscussionIf Se treatment reduces the progression of Chagas cardiopathy, the inclusion of this micronutrient in the daily diet can improve the therapeutic regimen for this neglected tropical disease at low cost.Trial registration: Clinical Trials.gov ID: NCT00875173 (registered 20 October 20 2008).
Source: Trials - October 6, 2014 Category: Journals (General) Authors: Pedro Alvarenga Americano do BrasilAndréa Pereira de SouzaAlejandro Hasslocher-MorenoSérgio XavierSonia Lambert PassosMaria de Fátima Ramos MoreiraMarília Santini de OliveiraGilberto Sperandio da SilvaRoberto Magalhães SaraivaClaudia Santos de Aguiar Source Type: research

Weight Loss Is a Useful Therapeutic Objective
Publication date: February 2015 Source:Canadian Journal of Cardiology, Volume 31, Issue 2 Author(s): Caroline K. Kramer Overweight/obesity has been associated with increased risk for several conditions, including hypertension, hypercholesterolemia, diabetes mellitus, heart disease, and stroke. The morbidity associated with overweight and obesity translates into excess mortality risk, which is observed even when increased weight is not associated with metabolic abnormalities. The achievement of moderate weight loss, regardless of the treatment strategy, is associated with favorable clinical outcomes, including significant...
Source: Canadian Journal of Cardiology - February 6, 2015 Category: Cardiology Source Type: research

Balancing risk and reward: a critical review of the intragastric balloon for weight loss
Worldwide, more than 1.4 billion adults are overweight or obese and either have or are at increased risk of numerous, potentially disabling conditions. In the United States, 68% of adults are overweight or obese, and the epidemic is spreading to children.1,2 Obesity is associated with a number of comorbidities including type 2 diabetes mellitus, coronary heart disease, sleep apnea, stroke, gallbladder and liver disease, musculoskeletal disease, and an increase in the prevalence of certain cancers.
Source: Gastrointestinal Endoscopy - April 14, 2015 Category: Gastroenterology Authors: Shantanu Gaur, Samuel Levy, Lisbeth Mathus-Vliegen, Ram Chuttani Tags: Review article Source Type: research

Diabetes mellitus related biomarker: the predictive role of growth-differentiation factor-15
Publication date: Available online 9 October 2015 Source:Diabetes & Metabolic Syndrome: Clinical Research & Reviews Author(s): Alexander E. Berezin Growth differentiation factor-15 (GDF-15) is a stress-responsive cytokine, which belongs to super family of the transforming growth factor beta. GDF-15 is widely presented in the various cells (macrophages, vascular smooth muscle cells, adipocytes, cardiomyocytes, endothelial cells, fibroblasts), tissues (adipose tissue, vessels, tissues of central and peripheral nervous system) and organs (heart, brain, liver, placenta) and it plays an important role in the ...
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - October 10, 2015 Category: Endocrinology Source Type: research

Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
Authors: Dailey GE Abstract Empagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces hyperglycemia in type 2 diabetes mellitus (T2DM) by decreasing renal glucose reabsorption and promoting urinary glucose excretion. In clinical trials, empagliflozin demonstrated significant improvements in glycemic control, as monotherapy and in combination regimens. In addition, empagliflozin was associated with weight loss and moderate reductions in blood pressure. In the EMPA-REG OUTCOME study, empagliflozin significantly reduced the risk of the composite primary endpoint of cardiovascular death, no...
Source: Drugs of Today - October 23, 2015 Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research

Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension
Purpose of review: The majority of patients with type 2 diabetes mellitus (T2DM) have hypertension requiring combination therapy. Sodium glucose cotransporter 2 (SGLT2) inhibitors are novel glucose-lowering drugs with shared and potentially unique beneficial effects on cardiovascular risk beyond glycemic control. This review focuses on the potential role of SGLT2 inhibitors in the treatment of hypertension associated with T2DM. Recent findings: SGLT2 inhibitors reduce office SBP by 3–5 mmHg and DBP by 2–3 mmHg across all class members. Corresponding clinically meaningful, significant blood pressure (BP) lowering e...
Source: Current Opinion in Nephrology and Hypertension - February 5, 2016 Category: Urology & Nephrology Tags: PATHOPHYSIOLOGY OF HYPERTENSION: Edited by Nancy J. Brown Source Type: research

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
Patients with type 2 diabetes mellitus (T2D) exhibit an increased risk for cardiovascular (CV) events. Hyperglycaemia itself contributes to the pathogenesis of atherosclerosis and heart failure (HF) in these patients, but glucose-lowering strategies studied to date have had little to no impact on reducing CV risk, especially in patients with a long duration of T2D and prevalent CV disease (CVD). Sodium glucose cotransporter-2 (SGLT2) inhibitors are a novel class of anti-hyperglycaemic medications that increase urinary glucose excretion, thus improving glycaemic control independent of insulin. The recently published CV outc...
Source: European Heart Journal - November 16, 2016 Category: Cardiology Authors: Marx, N., McGuire, D. K. Tags: Clinical update Source Type: research

Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies. I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact. Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications. Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news

What Are Endoscopic Bariatric Therapies?
The high prevalence of overweight and obesity in the United States negatively affects the health of the population. Obesity increases the risk of various diseases, including diabetes mellitus, hypertension, coronary heart disease, sleep apnea, stroke, gatroesophageal reflux disease, gall bladder disease, certain types of malignancy, and non-alcoholic fatty liver diseases.1,2 Reducing obesity in the United States has become a public health priority.1,2 Current approaches to therapeutic weight loss include dietary approaches, lifestyle intervention, pharmacology, and surgery.
Source: Journal of the American Dietetic Association - January 25, 2017 Category: Nutrition Authors: Wendy Marcason Tags: From the Academy Source Type: research

Late-life body mass index, rapid weight loss, apolipoprotein E ε4 and the risk of cognitive decline and incident dementia
ConclusionsHigher late-life BMI is associated with a lower risk of incident MCI and AD but is not protective in the presence of rapid weight loss.
Source: The Journal of Nutrition, Health and Aging - March 10, 2017 Category: Nutrition Source Type: research

Considerations and Treatment Options for Patients withComorbid Atrial Fibrillation and Diabetes Mellitus.
In conclusion, coexisting AF and DM represent a high risk population of patients requiring aggressive risk factor identification and treatment optimisation. The multifactorial interplay between these conditions requires individual assessment of patient risk profiles with the aim of minimising the impact of each modifiable risk factor. PMID: 28669216 [PubMed - as supplied by publisher]
Source: Expert Opinion on Pharmacotherapy - July 5, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Benefits of SGLT2 Inhibitors beyond glycemic control - A focus on metabolic, cardiovascular, and renal outcomes.
CONCLUSIONS: SGLT2 inhibitors demonstrate some positive metabolic effects. In addition, empagliflozin specifically has demonstrated reduction in cardiovascular events and delay in the progression of kidney disease in patients with T2DM and a history of cardiovascular disease. Further data is needed to assess if this is a class effect. PMID: 28814245 [PubMed - as supplied by publisher]
Source: Current Diabetes Reviews - August 16, 2017 Category: Endocrinology Authors: Minze MG, Will K, Terrell BT, Black RL, Irons BK Tags: Curr Diabetes Rev Source Type: research

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
Publication date: Available online 1 September 2018Source: Indian Heart JournalAuthor(s): A.K. PancholiaAbstractPatients with type 2 diabetes mellitus (T2DM) exhibit an increased risk for cardiovascular (CV) events. Hyperglycemia itself contributes to the pathogenesis of atherosclerosis and heart failure (HF) in these patients, but glucose-lowering strategies studied to date have had little or no impact on reducing CV risk, especially in patients with a long duration of T2DM and prevalent CV disease (CVD). Sodium glucose cotransporter-2 (SGLT2)-inhibitors are the new class of glucose lowering medications that increase urin...
Source: Indian Heart Journal - September 1, 2018 Category: Cardiology Source Type: research